Breaking Finance News

Zacks Investment Research downgraded Clovis Oncology Inc (NASDAQ:CLVS) to Hold in a report released today.

Zacks Investment Research has downgraded Clovis Oncology Inc (NASDAQ:CLVS) to Hold in a report released on 10/04/2016.

Previously on Friday September 23, 2016, Suntrust Robinson reported about Clovis Oncology Inc (NASDAQ:CLVS) raised the target price from $38.00 to $50.00. At the time, this indicated a possible upside of 0.29%.

Yesterday Clovis Oncology Inc (NASDAQ:CLVS) traded -1.67% lower at $34.80. The company’s 50-day moving average is $27.49 and its 200-day moving average is $18.25. The last stock close price is up 90.48% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 2,382,442 shares of the stock were exchanged, down from an average trading volume of 2,698,510

See Chart Below

Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology Inc has a 52 week low of $11.57 and a 52 week high of $109.18 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 8 brokers have issued a report on the stock. The consensus target price is $17.50 with 2 brokers rating the stock a strong buy, 0 equity analysts rating the company a buy, six equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.

Brief Synopsis About Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *